Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices 38921 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: August 10, 2017. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–17280 Filed 8–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Clinical and Translational R21 and Omnibus 

R03: SEP 3. 

Date: September 25–26, 2017. 

Time: 8:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Arlington Gateway, 801 

N. Glebe Road, Arlington, VA 22203. 

Contact Person: Robert Stephen Coyne, 

Ph.D., Scientific Review Officer, Research 

Program Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W236, Bethesda, MD 20892–9750, 

240–276–5120, coynes@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, R25 

Education. 

Date: September 27, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W608, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Robert E. Bird, Ph.D., 

Scientific Review Officer, Research Program, 

Review Branch Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W608, 

Bethesda, MD, 20892–9750, 240–276–6344, 

birdr@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project I. 

Date: October 12–13, 2017. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Anita T. Tandle, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W248, 

Bethesda, MD 20892–9750, 240–276–5007, 

tandlea@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Phase 

II Bridge Awards. 

Date: October 12, 2017. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Jeffrey E. DeClue Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W238, Bethesda, MD 20892– 

9750, 240–276–6371, decluej@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project II (P01). 

Date: October 17–18, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike Rockville, MD 20852. 

Contact Person: Sanita Bharti, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W122, 

Bethesda, MD 20892–9750, 240–276–5909, 

sanitab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project III (P01). 

Date: October 17–18, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Mukesh Kumar, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W618, 

Bethesda, MD 20892–9750, 240–276–6611, 

sanitab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Provocative 

Questions: SEP 4. 

Date: October 20, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Bethesda, MD 

20892–9750, 240–276–5122, hasan.siddiqui@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Clinical and Translational R21 and Omnibus 

R03: SEP–1. 

Date: October 25–26, 2017. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Byeong-Chel Lee, Ph.D., 

Scientific Review Officer Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W238, Bethesda, MD 20892–9750 

240–276–7755 byeong-chel.lee@nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group, NCI Clinical 

and Translational R21 and Omnibus R03: 

SEP–4. 

Date: October 25–26, 2017. 

Time: 6:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20892–9750. 

Contact Person: Eduardo E. Chufan, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Bethesda, MD 20892– 

9750, 240–276–7975, chufanee@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, R01 

Review Teleconference. 

Date: October 31, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W608, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Robert E. Bird, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W608, 

Bethesda, MD 20892–9750, 240–276–6344, 

birdr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
38922 Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 10, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–17279 Filed 8–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting for the 

Interdepartmental Serious Mental 

Illness Coordinating Committee 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Secretary of Health and 

Human Services (Secretary), in 

accordance with section 6031 of the 21st 

Century Cures Act, announces the 

inaugural meeting of the 

Interdepartmental Serious Mental 

Illness Coordinating Committee 

(ISMICC). The ISMICC will meet on 

August 31, 2017, from 9:00 a.m. to 5:00 

p.m., Eastern Time. The meeting will be 

held at the Hubert H. Humphrey 

Building, 200 Independence Avenue 

SW., Room 800, Washington, DC 20201. 

The meeting will include information 

on federal advances related to serious 

mental illness (SMI) and serious 

emotional disturbance (SED), including 

data evaluation, and recommendations 

for action. Committee members will also 

discuss workgroups, future meetings, 

and the Report to Congress. 

Members of the public can attend the 

meeting via telephone or webcast. The 

meeting can be accessed via webcast at 

www.hhs.gov/live. To obtain the call-in 

number and access code, submit written 

or brief oral comments, or request 

special accommodations for persons 

with disabilities, please register at the 

SAMHSA Advisory Committees Web 

site at https://www.samhsa.gov/aboutus/advisory-councils/smi-committee or 

contact Pamela Foote, Designated 

Federal Official (see contact information 

below). 

Interested persons may present data, 

information, or views, orally or in 

writing, on issues pending before the 

committee. Written statements should 

be submitted to the DFO on or before 

August 24, 2017. Oral presentations 

from the public will be scheduled at the 

conclusion of the meeting. Individuals 

interested in making oral presentations 

are encouraged to notify the DFO on or 

before August 24, 2017. Two minutes 

will be allotted for each presentation. 

Substantive meeting information and 

a roster of Committee members is 

available at the Committee’s Web site 

https://www.samhsa.gov/about-us/ 

advisory-councils/smi-committee or by 

contacting Pamela Foote, DFO. 

Committee Name: Interdepartmental 

Serious Mental Illness Coordinating 

Committee 

Dates/Time/Type: August 31, 2017/ 

9:00 a.m.—5:00 p.m./OPEN 

Place: Hubert H. Humphrey Building, 

200 Independence Avenue SW., Room 

800, Washington, DC 20201. Webcast 

and teleconference (see information 

above). 

DFO: Pamela Foote, Substance Abuse 

and Mental Health Services 

Administration, 5600 Fishers Lane, 

14E53C, Rockville, MD 20857; 

telephone: 240–276–1279; email: 

pamela.foote@samhsa.hhs.gov 

SUPPLEMENTARY INFORMATION: 

I. Background and Authority 

The ISMICC was established on 

March 15, 2017, in accordance with 

section 6031 of the 21st Century Cures 

Act, and the Federal Advisory 

Committee Act, 5 U.S.C. App., as 

amended, to report to the Secretary, 

Congress, and any other relevant federal 

department or agency on advances in 

serious mental illness (SMI) and serious 

emotional disturbance (SED), research 

related to the prevention of, diagnosis 

of, intervention in, and treatment and 

recovery of SMIs, SEDs, and advances in 

access to services and support for adults 

with SMI or children with SED. In 

addition, the ISMICC will evaluate the 

effect federal programs related to serious 

mental illness have on public health, 

including public health outcomes such 

as (A) rates of suicide, suicide attempts, 

incidence and prevalence of SMIs, 

SEDs, and substance use disorders, 

overdose, overdose deaths, emergency 

hospitalizations, emergency room 

boarding, preventable emergency room 

visits, interaction with the criminal 

justice system, homelessness, and 

unemployment; (B) increased rates of 

employment and enrollment in 

educational and vocational programs; 

(C) quality of mental and substance use 

disorders treatment services; or (D) any 

other criteria as may be determined by 

the Secretary. Finally, the ISMICC will 

make specific recommendations for 

actions that agencies can take to better 

coordinate the administration of mental 

health services for adults with SMI or 

children with SED. Not later than 1 

(one) year after the date of enactment of 

the 21st Century Cures Act, and 5 (five) 

years after such date of enactment, the 

ISMICC shall submit a report to 

Congress and any other relevant federal 

department or agency. 

II. Structure, Membership, and 

Operation 

This ISMICC consists of federal 

members listed below or their 

designees, and non-federal public 

members. 

Federal Membership: The ISMICC 

will be composed of the following 

federal members or their designees: The 

Secretary of HHS; The Assistant 

Secretary for Mental Health and 

Substance Use; The Attorney General; 

The Secretary of the Department of 

Veterans Affairs; The Secretary of the 

Department of Defense; The Secretary of 

the Department of Housing and Urban 

Development; The Secretary of the 

Department of Education; The Secretary 

of the Department of Labor; The 

Administrator of the Centers for 

Medicare and Medicaid Services; and 

The Commissioner of the Social 

Security Administration. 

Non-federal Membership: The ISMICC 

includes 14 non-federal public members 

appointed by the Secretary representing, 

psychologists, psychiatrists, social 

workers, peer support specialists, and 

other providers, patients, family of 

patients, law enforcement, the judiciary, 

and leading research, advocacy, or 

service organizations. A roster of 

Committee members is available at the 

Committee’s Web site: https://

www.samhsa.gov/about-us/advisorycouncils/smi-committee. The term of 

office of an ISMICC non-federal member 

is three years, and is subject to 

reappointment to serve for one or more 

additional three-year terms. If a vacancy 

occurs in the ISMICC among the 

members, the Secretary shall make an 

appointment to fill such vacancy within 

90 days from the date the vacancy 

occurs. Any member appointed to fill a 

vacancy for an unexpired term shall be 

appointed for the remainder of such 

term. A member may serve after the 

expiration of the member’s term until a 

successor has been appointed. Initial 

appointments shall be made in such a 

manner as to ensure that the terms of 

the members will not all expire in the 

same year. The ISMICC is required to 

meet twice per year. 

Carlos Castillo, 

Committee Management Officer. 

[FR Doc. 2017–17187 Filed 8–15–17; 8:45 am] 

BILLING CODE 4162–20–P 


asabaliauskas on DSKBBXCHB2PROD with NOTICES